Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 13/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30258583 | 0.90 | PARP1 (0.43) | PARP1KEAP1PTGDR2NFE2L2ATM | |
| SCHEMBL30256409 | 0.90 | PARP1 (0.43) | PARP1KEAP1PTGDR2NFE2L2ATM | |
| SCHEMBL30258676 | 0.86 | KEAP1 (0.52) | KEAP1NFE2L2ATML3MBTL1ALDH1A1 | |
| SCHEMBL23930720 | 0.86 | KEAP1 (0.52) | KEAP1NFE2L2ATML3MBTL1ALDH1A1 | |
| SCHEMBL23930764 | 0.85 | KEAP1 (0.45) | KEAP1NFE2L2ATML3MBTL1ALDH1A1 | |
| SCHEMBL28594808 | 0.84 | KEAP1 (0.48) | KEAP1NFE2L2ATML3MBTL1ALDH1A1 | |
| SCHEMBL28589283 | 0.83 | KEAP1 (0.44) | PARP1KEAP1NFE2L2ATML3MBTL1 | |
| SCHEMBL25555646 | 0.82 | TSHR (0.41) | PARP1KEAP1PTGDR2ALDH1A1NOTUM | |
| SCHEMBL25551915 | 0.82 | TSHR (0.41) | PARP1KEAP1PTGDR2ALDH1A1NOTUM | |
| Hydrochloric Acid SCHEMBL30258420 | 0.81 | TSHR (0.40) | PARP1KEAP1PTGDR2ALDH1A1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159511-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | C4X DISCOVERY LIMITED (GB) | 2023-05-25 | — | — | US | disclosed |
| EP-4139295-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | C4x Discovery Limited (GB) | 2023-03-01 | — | — | EP | disclosed |
| CN-115667242-A | Tetrahydroisoquinoline compounds as NRF2 activators | 希四克斯探索有限公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2021214472-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | C4X DISCOVERY LIMITED (GB) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159511-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | NFE2L2, KEAP1, NQO1 | PARP1 950/4885KEAP1 2/4885PTGDR2 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.